The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2019 | Allo-SCT upfront for MCL: feasible for a small subgroup?
Simon Rule, MD, Plymouth University, Plymouth, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He discusses his research on the use of allogeneic stem cell transplantation as part of front-line therapy for mantle cell lymphoma (MCL), with results suggesting that this option should only be considered in a subgroup of patients at high risk of early progression following conventional therapy.
